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INTRODUCTION
The prevalence of developmental disabilities is 13.87% 
across all racial, ethnic, and socioeconomic groups, and 1 in 
33 babies is born with congenital anomalies in the United 
States.1,2 Frequently, persons with developmental disabilities 
 (developmental delay and/or intellectual disability (DD/ID)) 
present with one or more congenital anomalies or dysmorphic 
features. These affected individuals have lifelong challenges, 
including difficulties with physical movement, learning, and 
social interaction. Early intervention is important for providing 
better outcomes for these children with special needs. Despite 
this, on average, diagnosis of developmental disability in chil-
dren does not occur until they have reached the age of 4 years, 
or 2.6 years in children with developmental disability and intel-
lectual disability.3 Establishing an underlying diagnosis early 
has the potential to reduce health-care costs and provide physi-
cians and families with information about the disorder affect-
ing the child, prognosis, and comorbidity, all of which have 
implications beyond medical treatment.
Historically, with the use of traditional cytogenetic tech-
niques such as karyotyping and fluorescence in situ hybridiza-
tion (FISH), only a relatively small fraction of patients (~6%) 
were successfully diagnosed, owing to limits on resolution. 
However, in recent years, with the advent of new techniques 
such as the chromosomal microarray (CMA), the yield has 
increased ~10–18%.4,5 Additionally, it was recently reported 
by Shashi et al.6 that when a combination of laboratory tools 
including a microarray was used, 46% of patients suspected 
of having a genetic disease were diagnosed and 72% of these 
diagnoses were made on the first visit. The authors also 
showed that a genetic diagnosis in a patient leads to an aver-
age cost reduction of more than $1,435 in direct genetic labo-
ratory tests (including number of visits to diagnosis and cost 
of all genetic tests performed) as compared with undiagnosed 
patients.  This is likely a gross underestimate of the true savings 
because this reports only one portion of typical costs incurred 
for these patients. It has also been reported that microar-
ray analysis in support of a patient’s standard of care impacts 
patient management up to 70% of the time.7–10 Because clini-
cal management decisions are sometimes subjective, the per-
centages vary. In two large retrospective studies representing 
slightly less than a total of 75,000 patients, it was estimated that 
35–46% of patients with pathogenic cytogenetic findings and 
7% of all patients would have some sort of change in clinical 
management based on microarray results.7,8 Two other stud-
ies reported on retrospective cohorts for which actual rates of 
clinical implications were available and found that more than 
50% of all patients with abnormalities had clinical management 
changes based on microarray results.9,11 Although microarrays 
are now common first-tier tests in this patient population and 
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Purpose: The prevalence of developmental disabilities in the United 
States is reported to be 13.87% across all racial, ethnic, and socio-
economic groups. Microarrays have been recommended as first-tier 
tests for these patients. This study reports the diagnostic yield and 
potential actionability of findings using a high-density chromosomal 
microarray (CMA).
Methods: The diagnostic yield of CytoScan Dx Assay in 960 patients 
was assessed with the Riggs criteria of actionability to evaluate pre-
dicted clinical utility.
Results: Eighty-six percent of the subjects were assessed using a 
microarray as part of historical routine patient care (RPC). The rate of 
pathogenic findings was similar between RPC (13.3%) and the Cyto-
Scan Dx Assay (13.8%). Among the 138 patients who did not receive 
microarray as RPC, the diagnostic yield for CytoScan Dx Assay was 
23.9% as compared with 14.5%, indicating a 9.4% improvement when 
using higher-resolution methods. Thirty-five percent of patients with 
abnormal findings had predicted clinical management implications.
Conclusions: This is the first study to assess the clinical performance 
of CytoScan Dx Assay. The assay’s diagnostic yields are similar to 
those found in other studies of CMAs. Thirty-five percent of patients 
with abnormal findings are predicted to have clinical management 
implications that may improve health outcomes.
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supported by medical guidelines from the American College of 
Medical Genetics and Genomics (ACMG),12 the International 
Collaboration for Clinical Genomics (ISCA/ICCG),5 and the 
American Academy of Neurology,13 payer reimbursement for 
testing is inconsistent, indicating the need for additional sys-
tematic studies assessing the changes in patient management 
that occur as a result of microarray testing.
In a consecutive cohort of 960 patients who had previously 
undergone standard genetic testing for suspicion of a genetic 
disorder related to DD/ID, congenital anomalies, and/or dys-
morphic features, we assessed the diagnostic yield of the 
CytoScan Dx Assay as compared with historical patient reports 
or routine patient care (RPC). To determine how this relates 
to management implications, we assessed the clinical utility of 
the CytoScan Dx Assay by applying the Riggs criteria of action-
ability to the chromosomal abnormalities identified by the 
CytoScan Dx Assay. In 2013, Riggs et al.8 published an article 
describing 186 phenotypes that were clinically actionable, 
potentially diagnosable via CMA, and that are causally linked 
to specific genes and/or chromosomal loci (see Supplementary 
Table S1 online). They further ranked each phenotype accord-
ing to the level of evidence available. Clinical actionability was 
described as requiring at least one of the following recom-
mended interventions for the patient: (i) referral to a special-
ist, (ii) further diagnostic testing, (iii) surgical/interventional 
procedure (indicated or contraindicated), (iv) surveillance, 
(v) medication (prescribed or contraindicated), (vi) lifestyle 
changes, and (vii) other.
MATeRIALS AND MeTHODS
Patient samples
Surplus samples from patients who underwent chromosomal 
testing were collected from July 2009 to July 2012 at three 
laboratories: Greenwood Genetic Center (Greenwood, SC), 
CombiMatrix (San Diego, CA), and the Mayo Clinic (Rochester, 
MN). Study inclusion criteria were applied to samples as 
follows: (i) DNA samples from postnatal patients referred for 
chromosomal analysis based on suspicion of DD/ID, congenital 
anomalies, and/or dysmorphic features; (ii) prospectively col-
lected or retrospectively banked gDNA (genomic DNA) sam-
ples if they were collected from consecutive patients meeting the 
study criteria during a specified period of time; (iii) sample type 
was blood-derived gDNA; (iv) gDNA samples extracted from 
whole blood collected using either ethylenediaminetetraace-
tic acid or heparin blood collection tubes; (v)  gDNA sample 
concentration was >150 ng/µl via optical density measurement 
or ≥75 ng/µl via PicoGreen (Life Technologies, Eugene, OR) 
measurement and diluted in 1× Molecular Grade TE Buffer 
(Affymetrix, Santa Clara, CA) pH 8.0; (vi) gDNA sample vol-
ume was ≥20 µl; and (vii) gDNA sample had been analyzed 
using a whole-genome analysis method (e.g., microarray, karyo-
type) and both the test results and patient diagnostic report 
could be provided. Samples were excluded if the gDNA sample 
was analyzed using any Affymetrix microarray as part of RPC 
to avoid self-comparison of Affymetrix microarrays. This study 
was approved by the institutional review boards of Greenwood 
Genetic Center, Mayo Clinic, and CombiMatrix Diagnostics.
Genetic analyses
Routine patient care (RPC) at these institutions varied and may 
have comprised one or more copy-number methods such as 
karyotype, FISH, CMA (excluding any Affymetrix array), poly-
merase chain reaction, or multiplex ligation-dependent probe 
amplification. Each institution’s qualified cytogeneticist or 
molecular pathologist generated an overall clinical laboratory 
interpretation for each sample and also assessed each of the 
chromosomal copy-number variant (CNV) regions reported 
in each sample and classified them as benign, pathogenic, or 
variant of unknown significance (VOUS). Samples were then 
provided to Affymetrix (Santa Clara, CA) for further analy-
sis. gDNA samples were run at Affymetrix laboratories on the 
CytoScan Dx Assay, and results were provided to an indepen-
dent cytogeneticist who generated an overall clinical laboratory 
interpretation for each sample, including a syndrome diagno-
sis, if appropriate. The cytogeneticist also assessed each of the 
sample’s CNVs and classified them as benign, pathogenic, or 
VOUS. The cytogeneticist was permitted to request parental 
results; if the results were requested and available as part of RPC 
at the clinical laboratory of origin, then the cytogeneticist was 
permitted to use them to complete his interpretation. Neither 
the original clinical laboratory diagnosis nor data from test-
ing conducted during RPC such as karyotyping, FISH, CMA, 
polymerase chain reaction, multiplex ligation- dependent 
probe amplification, or any other type of copy-number data 
were available to the cytogeneticist when interpreting the 
CytoScan Dx Assay results. All of the clinical and laboratory 
Table 1 Clinical interpretation results
Routine patient care classification
Total Pathogenic Nonpathogenic
VOUS Benign No CNVs
Pathogenic 132 105   7   0  20
CytoScan Dx clinical 
classification
Nonpathogenic VOUS 371  22  81  69 199
Benign 457   1  21  44 391
Total 960 128 109 113 610
CNV, chromosomal copy-number variant; VOUS, variant of unknown significance.
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data were  de-identified prior to entry into DATATRAK EDC 
(DATATRAK International, Mayfield Heights, OH; version 
12.0.0) by the participating institution; monitoring for data 
quality was conducted by a clinical research organization 
(Pharm-Olam International, Houston, TX).
Data analysis
Using Human Genome Build 19 (Genome Reference 
Consortium GRCh37), CytoScan Dx Assay CNV coordinates 
were compared with the coordinates of actionable microarray 
findings listed in the study by Riggs et al.8 There were two match-
ing classifications. In the first, if the Riggs region was character-
ized as a chromosomal region and did not have a specific gene 
implicated, then the region had to be fully enclosed within a 
CytoScan Dx Assay CNV region. In the second, if Riggs char-
acterized a specific gene as the region of significance, a match 
was considered when there was any overlap with a CytoScan Dx 
Assay CNV (i.e., any overlap would disrupt the gene and func-
tion). Rates and descriptive statistics are reported. Calculations 
were performed using Microsoft Excel 2010.
ReSULTS
A total of 1,171 samples were collected from the three partici-
pating sites. Each site confirmed screening of consecutive sub-
jects for inclusion into the study. One hundred fifty-six samples 
failed to meet inclusion criteria; 96.8% of the screen failures 
were due to low sample availability (gDNA sample ≤20 µl) or 
low gDNA concentration and were excluded from the study. 
Consequently, a total of 1,015 postnatal blood-derived gDNA 
samples were collected and submitted to Affymetrix.  Forty-eight 
of these samples failed incoming DNA  quality-control met-
rics and were excluded. Therefore, 967 gDNA samples were 
determined to be eligible for CytoScan Dx Assay. On sample 
processing, two samples failed array quality-control metrics, one 
sample was highly segmented (>1,000 segments and unable to 
be loaded into the data-management system) and was not sent 
for interpretation, and four were excluded by the cytogeneticist 
as being uninterpretable because of the high number of CNV 
segments; therefore, the final analysis data set contained 960 
samples. Supplementary Figure S1 online illustrates the sample 
disposition and the number of samples included in the analyses.
Site 1 contributed 49.7% of the samples in the study, and sites 
2 and 3 contributing 20.6 and 29.7%, respectively. The aver-
age age of subjects was 7.8 ± 11.3 years, and 61.7% were male. 
Overall, 86% of the subjects had been previously assessed using 
a microarray as part of RPC. Four hundred twenty-five CNVs 
were reported by the investigative sites versus 10,743 identified 
on CytoScan Dx Assay, which translates into 11.2 ± 4.1 CNVs 
per patient. Sites varied in reporting criteria and did not rou-
tinely report every CNV identified.
Diagnostic yield and absence of heterozygosity
The diagnostic yield (calculated as the rate of pathogenic find-
ings) was similar between RPC (13.3% or 128/960) and the 
CytoScan Dx Assay (13.8% or 132/960) (Table  1) and 23.9% 
or 33/138 (95% confidence interval, 17.6–31.7%) as compared 
with 14.5% or 20/138 (95% confidence interval, 9.6–21.3%) 
in individuals who did not receive microarray as RPC. These 
differences were not statistically significant due to the wide 
confidence interval based on the small sample size of individu-
als who did not receive a microarray as part of RPC. Absence 
of heterozygosity (AOH) was reported by the cytogeneticist 
interpreting CytoScan Dx Assay results in 91 patients. AOH 
regions were reported on a variety of chromosomes and had 
sizes ranging from 5 to 649 Mb; the median size was 11.7 Mb. 
Uniparental disomy was identified that predicted a diagnosis 
of Prader-Willi or Angelman in one sample. However, because 
AOH results were not requested from RPC, no comparison is 
possible. However, obtaining AOH information in addition to 
copy-number information from the same platform is known to 
maximize the diagnostic yield from array testing.14
Predicted clinical utility
Of the patients with pathogenic findings (comprising 58 
CNVs) identified by CytoScan Dx Assay, 35% or 46/132 had 
predicted clinical management implications. One patient 
Figure 1 Classification of CytoScan Dx Assay results and predicted clinical management changes.
All cases
(n = 960)
Normal CytoScan Dx result
(n = 457)
No change
recommended
(n = 457, 100%)
No change
recommended
(n = 370, 99%)
Clinical Management
change
recommended
(n = 1, <1%)
Clinical management
change
recommended
(n = 46, 35%)
No change
recommended
(n = 86, 65%)
VOUS CytoScan Dx result
(n = 371)
Abnormal CytoScan Dx result
(n = 132)
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was identified by use of AOH information with a diagnosis 
of  Prader-Willi/Angelman. Another patient was identified 
as having a VOUS and was recommended for management 
changes (Figure 1). The VOUS case was a woman with ~60-
Kb copy gain (CN state of 3; chr17:15,136,578-15,196,703 
[hg19]) of the PMP22 gene (exons 1–4; CCDS11168.1). 
This copy gain is considerably smaller than the 1.5-Mb 
 classical Charcot-Marie-Tooth type 1a (CMT1A) duplication 
(chr17:13,968,607-15,434,038[hg19]). However, this find-
ing implicates significant clinical management that would be 
applicable for CMT1A patients.
Most commonly, 16p13.11 microduplication syndrome was 
diagnosed, followed by 22.q11.2-related cardiac phenotype. 
Table 2 provides the phenotypes with documented clinical man-
agement implications that were identified in the current study.
The RPC did not routinely report all identified CNVs, so a 
comparison with the predicted clinical management changes 
using the Riggs criteria identified by CytoScan Dx Assay is not 
possible.
CytoScan Dx Assay identified 20 additional abnormal CNVs 
in historical patient reports, 25% of which had predicted clini-
cal management implications (Table 3).
To illustrate the clinical utility of CytoScan Dx Assay, one 
of the patients was a 20-month-old boy of African-American 
ethnicity who presented in the clinic for the evaluation of DD, 
hypotonia, low weight, and microcephaly. There were no peri-
natal complications, although he had been born at 36½ weeks. 
Previous magnetic resonance imaging yielded normal results. 
Family history revealed that he had three older half-siblings, 
one of whom had a history of attention-deficit hyperactivity 
disorder and another who had history of heart surgery for a 
heart murmur. Physical examination at the time of evaluation 
showed a weight of 9.9 kg (second percentile), height of 80.5 cm 
(15th percentile), and head circumference of 44.5 cm (less than 
second percentile). He sat at approximately 12 months of age 
and made some nonspecific sounds (babbling). This individual 
was very social and interactive. He had no major dysmorphic 
features (except a flat nasal bridge), and the cardiovascular 
examination results were noncontributory. However, neuro-
logical examination revealed mild truncal hypotonia. RPC 
genetic testing included karyotyping, methylation studies 
for  Prader-Willi/Angelman syndrome, fragile-X testing, and 
myotonic dystrophy testing, all of which had normal results. 
CytoScan Dx Assay identified a deletion of 7q11.23, which is 
consistent with a clinical diagnosis of Williams-Beuren syn-
drome (WBS). WBS is a contiguous gene deletion syndrome 
in patients presenting with ID, hypercalcemia, hypercalciuria, 
hypothyroidism, failure to thrive in infancy, supravalvar aor-
tic stenosis, distinctive facial features, stellate iris, hoarse voice, 
hernia, rectal prolapse, and joint limitation or laxity. The gen-
eral recommendations for management of this disorder call for 
aggressive therapies and screening. Ophthalmologic evalua-
tion, kidney ultrasound, thyroid testing, and total and ionized 
calcium level testing are some routine evaluations that are rec-
ommended, demonstrating the complexity in clinical manage-
ment of WBS.
Several microdeletion/microduplication syndromes were 
identified by CytoScan Dx (and missed by RPC) in this study, 
including (but not limited to) 3q29 microduplication, 22q11 
microduplication, 16p11.2 microduplication, 16p11.2 micro-
deletion, KBG syndrome, and Floating-Harbor syndrome. 
Some of these cases would have warranted significant clinical 
management at the time of diagnosis, whereas for others find-
ing a genetic cause would have ended the diagnostic odyssey. 
However, because the RPC deemed these cases normal, no 
other follow-up information was provided by the respective 
sites for this study.
DISCUSSION
The current study was conducted to assess the clinical perfor-
mance of CytoScan Dx Assay in patients with DD, ID, and/or 
congenital anomalies who were referred for whole-genome 
Table 2 Description of the patient phenotypes that have 
clinical management implications
Phenotype with documented clinical management 
implications
No. of 
patients
16p13.11 duplication syndrome 7
22q11.2-related cardiac phenotype 5
1q21.1 deletion syndrome 4
Familial pulmonary fibrosis 4
Neurofibromatosis type 1 4
Supravalvular aortic stenosis 3
16p13.11 microdeletion syndrome 2
1q21.1 duplication syndrome 2
Angelman syndrome 2
MECP2 duplication syndrome 2
Steroid sulfatase deficiency; X-linked ichthyosis 2
16p11.2 duplication syndrome 1
22q11.2 deletion syndrome 1
46,XY complete gonadal dysgenesis/disorder of sex 
development
1
Autism spectrum disorders 1
Charcot-Marie-Tooth type 1a 1
Duchenne/Becker muscular dystrophy 1
Holoprosencephaly 1
Kleefstra syndrome 1
MAPT-related disorders 1
Pelizaeus-Merzbacher disease 1
Phelan-McDermid syndrome 1
Polycystic kidney disease 1
PTEN hamartoma tumor syndrome 1
Retinoblastoma 1
Smith Magenis 1
Von-Hippel Lindau 1
Wolf-Hirschhorn syndrome 1
 MAPT, microtubule-associated protein tau; PTEN, phosphatidylinositol 
3,4,5-trisphosphate 3-phosphate and dual-specificity protein phosphatase.
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chromosomal testing. CytoScan Dx Assay identified rare patho-
genic CNVs in 13.8% of these patients. This diagnostic yield is 
comparable to previous reports of historical RPC, which often 
used microarrays to assess these patients, and it is also consis-
tent with the published literature on diagnostic yield in this 
patient population.4,5,15 This study was originally designed to 
meet US Food and Drug Administration requirements and the 
interpreting cytogeneticist did not have access to any comple-
mentary information, as is standard in laboratory analysis (i.e., 
clinical data or supplementary laboratory testing). To obtain a 
more realistic view of CytoScan Dx Assay’s diagnostic yield, it 
may be useful to reanalyze this data set with the complete labo-
ratory information available to a qualified cytogeneticist.
Importantly, this study illustrates that one-third of patients 
with an abnormal chromosomal anomaly identified by 
CytoScan Dx Assay have predicted clinical management 
changes with levels of evidence of 1–3. Riggs et al. reported 
that 46% of all pathogenic or likely pathogenic CNVs submit-
ted to their database had management implications with levels 
of evidence of 1 or 2. This difference in percentage could be 
due to the fact that their cohort was not a consecutive series 
but, rather, a freeze of a database to which many laboratories 
submit array results. Level 1 evidence is described as practice 
guidelines endorsed by a professional society, level 2 evidence 
is peer-reviewed publications available for making medical 
management recommendations, and level 3 evidence indi-
cates that there are no relevant peer-reviewed publications but 
potential management implications may be warranted based 
on clinical judgment (see Riggs et al.8 for a full description of 
the evidentiary levels). The current study did not have a cat-
egory for “likely pathogenic” as the Riggs cohort did, and the 
cytogeneticist interpreting the results of this study did so in 
isolation, i.e., did not have access to any clinical information 
about these patients and very little data regarding parental 
results. Nonetheless, even if we were to remove CNVs with a 
level of evidence of 3 for management implications, only six 
patients would be removed from the list of clinically action-
able subjects, which means that this consecutive cohort still 
Table 3 Additional CNVs identified by CytoScan Dx Assay
Sex Age RPC methoda Chr
Genomic coordinates (hg19) Primary CNV/syndrome Clinical 
management 
implicationStop Stop Identified by CytoScan Dx Assay
F 2 Karyotype, methylation chr5 88031638 88446608 5q14.3 deletion No
F 5 Karyotype, PCR chr22 18916843 21465659 22q11 microduplication No
F <1 Karyotype, PCR chr16 29432245 30240227 16p11.2 microduplication Yes
F 14 Microarray,a karyotype, 
PCR
chr3 195725291 197386180 3q29 microduplication No
M 2 Microarray,a karyotype, 
FISH, PCR
chr16 30609032 30765430 Floating-Harbor syndrome No
M 2 Karyotype, PCR, 
methylation
chr7 72691243 74141512 Williams-Beuren syndrome Yes
M 2 Karyotype chr12 19597206 21972819 2.5 Mb deletion on 12p No
M 11 Karyotype chr5 56561970 68212088 11 Mb deletion on 5q11.2-q13.1 No
M 14 Microarray,a karyotype, 
PCR
chr16 89376153 89490401 KBG syndrome or ANKRD11 (ankyrin 
repeat domain 11) gene deletion
No
M 3 Microarray,a karyotype, 
PCR
chr9 139907011 140180810 273 kb deletion on 9q34.3 No
M 3 Karyotype, PCR chr16 29567296 30177916 16p11.2 microdeletion No
F 6 Karyotype chrX 31774321 31947969 Duchenne/Becker muscular dystrophy No
F 7 Karyotype chrX 168547 8393904 Turner syndrome No
F 0 Karyotype chr17 29356946 30386515 Neurofibromatosis 1 with intellectual 
disability
Yes
F 3 Karyotype chr16 15364267 18231275 16p13.11 microduplication Yes
F 0 Karyotype chr12 173787 2121136 2 Mb loss 12pter; 9.3 Mb gain 21qter No
F 28 Karyotype chr16 29567296 30177916 16p11.2 microdeletion No
F 0 Karyotype chr22 18937513 21465659 22q11 microduplication No
F 7 Microarraya chr15 22752398 102429049 Angelman/Prader-Willi No
F 0 Karyotype chr22 18644791 21800797 DiGeorge/velocardiofacial/22q11.21 
microdeletion
Yes
CNV, chromosomal copy-number variant; FISH, fluorescence in situ hybridization; PCR, polymerase chain reaction; RPC, routine patient care.
aNon-Affymetrix Microarray.
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predicts that 30% (40/132) of pathogenic CNVs would neces-
sitate clinical management changes.
It is now commonly known that high-resolution whole-
genome CMAs such as CytoScan Dx Assay have the ability to 
identify CNVs that may be missed by other technologies such 
as karyotyping, FISH, and targeted or lower-resolution array 
platforms due to inadequate coverage and/or lower resolution. 
Finding these CNVs can end the diagnostic odyssey for patients 
and families, potentially reduce health-care costs by avoiding 
unnecessary testing, provide additional information to inform 
reproductive health for family planning, and substantially affect 
patient care. In this cohort, CytoScan Dx Assay identified an 
additional 20 CNVs compared with the RPC results, which 
typically used one or more methods of chromosomal analysis; 
25% of these additional CNVs would result in predicted clinical 
management changes.
There are several limitations of our study. The comparison 
of the diagnostic yield of RPC with that of CytoScan Dx Assay 
is confounded by the fact that laboratories that interpreted the 
historical RPC results may have had access to complemen-
tary laboratory results and parental data, whereas the cyto-
geneticist interpreting the results from CytoScan Dx Assay 
did not have access to clinical or accompanying laboratory 
information and access to parental testing was extremely lim-
ited. Another limitation is that the patient cohort reported 
here was not necessarily evaluated with microarrays as a first-
tier test. Many of the known, actionable CNVs are larger and 
based on  lower-resolution platforms. Over the past 3–5 years, 
 high-resolution platforms have identified many small CNVs 
that underlie ID/DD disorders and therefore may lead to 
increases in diagnostic yield and the actionable rate for some of 
these patients.16 Finally, the comparison with the Riggs criteria 
is predictive in nature and not a reflection of actual practice. 
Future studies should be prospective and follow patients for 
actual clinical management changes.
Conclusion
In conclusion, this is the first study to assess the clinical perfor-
mance of CytoScan Dx Assay in a consecutive cohort of patients 
with DD, ID, and/or congenital anomalies who were referred 
for whole-genome chromosomal testing. CytoScan Dx Assay’s 
diagnostic yields are similar to those reported in previous 
studies, with 13.8 and 35% of patients with pathogenic CNVs 
identified by CytoScan Dx Assay predicted to have clinical 
management implications that may improve health outcomes.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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